Oasmia Pharmaceutical AB develops, manufactures, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. It focuses on manufacturing formulations based on cytostatics. The company's approved products include Paclical/Apealea for the treatment of ovarian and metastatic breast cancer; and Doxophos for the treatment of various doxorubicin indications. It also develops Docecal for breast cancer; OAS-19 and KB9520 for various cancers; Paccal Vet for mammary carcinoma and squamous cell carcinoma; and Doxophos Vet for lymphoma. Oasmia Pharmaceutical AB was founded in 1988 and is based in Uppsala, Sweden.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [07/30/2019 08:01 PDT] OASM Expected to Trade Up After Bullish Patterns Develop
• [07/11/2019 21:21 PDT] Market Maker Surveillance Report. OASM, Losing Stocks With Lowest Price Friction For Thursday, July 11th 2019
• [07/10/2019 21:21 PDT] Market Maker Surveillance Report. OASM, Losing Stocks With Lowest Price Friction For Wednesday, July 10th 2019
• [07/10/2019 08:06 PDT] OASM Expected to Trade Up Short Term
• [06/28/2019 21:21 PDT] Market Maker Surveillance Report. OASM, Losing Stocks With Lowest Price Friction For Friday, June 28th 2019
• [06/27/2019 10:30 PDT] Oasmia Pharmaceutical AB (publ) (NASDAQ:OASM), Up By 100.00% ($1.26) From $1.260 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [06/26/2019 08:07 PDT] OASM Expected to Trade Up After Bullish Patterns Develop